NeuroTech.com
News & Insights

Neurotech industry news

Funding rounds, product launches, research findings, and policy updates — published 3× per week.

Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Target Brain HealthFunding

Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Target Brain Health

Catalio-backed neuroscience startup Flourish has launched with investment from Bezos Expeditions and Google Ventures.

2026-07-11

BrainCo Pushes to Commercialize Brain-Tech as China's BCI Ambitions Come Into FocusIndustry

BrainCo Pushes to Commercialize Brain-Tech as China's BCI Ambitions Come Into Focus

CNBC profiles BrainCo's commercialization drive, spotlighting China's growing ambition to compete at the frontier of brain-computer interface technology.

2026-07-10

FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical ReachPolicy

FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical Reach

The FDA has cleared the PoNS neurostimulation device for stroke rehabilitation, extending its approved use beyond multiple sclerosis.

2026-07-09

Neurovalens Wins FDA Approval for PTSD Therapy Targeting US VeteransPolicy

Neurovalens Wins FDA Approval for PTSD Therapy Targeting US Veterans

Neurovalens has received FDA approval for its non-invasive neuromodulation therapy to treat PTSD in US veterans.

2026-07-08

University of Michigan Completes First Long-Term Wireless Brain-Computer Interface Implant in HumansResearch

University of Michigan Completes First Long-Term Wireless Brain-Computer Interface Implant in Humans

U-M neurosurgeons perform the first long-term wireless BCI implant in a human patient, marking a pivotal milestone for the field.

2026-07-07

Synchron Closes $275M Series E to Accelerate Stentrode BCI CommercializationFunding

Synchron Closes $275M Series E to Accelerate Stentrode BCI Commercialization

Synchron raises $275M Series E to expand Stentrode BCI trials and push toward FDA approval for paralysis patients.

2026-06-29

It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion AssessmentsProduct

It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments

FacialDx analyzes over 13,000 facial variables and 155 biomarkers to deliver neurological wellness indicators in seconds — giving clinicians objective data for sideline concussion decisions.

2026-06-23

MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% AccuracyResearch

MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy

MIT's new EEG-based system decodes six discrete emotional states in real time with 94% accuracy, a landmark for non-invasive affective neuroscience.

2026-06-13

Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical SettingsProduct

Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings

Synchron's Stentrode Home Edition brings endovascular BCI technology to approved patients outside hospital walls for the first time.

2026-06-11

Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal TrialIndustry

Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial

Synchron's implantable brain-computer interface has now been placed in 100 patients globally, setting the stage for a pivotal FDA trial later this year.

2026-06-09

Closed-Loop Deep Brain Stimulation Demonstrates Sustained Cognitive Benefits in Landmark Alzheimer's TrialResearch

Closed-Loop Deep Brain Stimulation Demonstrates Sustained Cognitive Benefits in Landmark Alzheimer's Trial

A 24-month adaptive DBS trial reports significant memory retention improvements in early-stage Alzheimer's patients, reshaping neuromodulation research.

2026-06-04

FDA Finalizes Guidance Framework for Adaptive Neural Devices, Setting Clearer Path for BCI ApprovalsPolicy

FDA Finalizes Guidance Framework for Adaptive Neural Devices, Setting Clearer Path for BCI Approvals

The FDA's finalized guidance on adaptive neural devices establishes new evidentiary standards for BCI approvals, reshaping the regulatory landscape.

2026-05-30

Sponsored content

Reach neurotech decision-makers with your story

Sponsored articles appear in the News feed and the weekly newsletter. $1,500/article.

Learn more →